Amnis Therapeutics

Endovascular Technologies for Emergency Situations

Health Tech & Life Sciences
Non Active, Jul 2021 ceased to operate
Mature Or Akiva, Israel Founded 2007
LinkedIn
Last updated 2026-06-18
Total raised
$400K
Last: 2017-05
Stage
Mature
Founded
2007
Headcount
1-10
HQ
Or Akiva, Israel
Sector
Health Tech & Life Sciences

About

Amnis Therapeutics is a biomedical engineering company specializing in developing, manufacturing, and marketing lifesaving endovascular technologies for emergency situations. Its mission is to provide the medical community with innovative, high-performance devices that offer a reliable, proven solution for numerous endovascular indications. The companys AneugraftDx is a pericardium covered coronary stent for emergency vessel reconstruction in cases of acute rupture or dissection of a coronary artery, coronary aneurysm, or saphenous vein graft reperfusion. The AneugraftNx is a neurovascular pericardium covered stent designed specifically for intracranial indications such as aneurysms, ruptures, and cavernous carotid fistulas (CCFs). The innovative, biologically covered stents provide immediate blood vessel reconstruction in a one-step procedure. In addition to its covered stent technology, Amnis Therapeutics is expanding its product development to include other unique solutions for emergency intra-arterial interventions. The most recent of these products is the Golden Retriever, a mechanical neurothrombectomy device for the emergency treatment of acute ischemic stroke.

Funding history · 2 rounds · $400K total

2017-05
Undisclosed
2016-05

Q&A

What is Amnis Therapeutics' primary focus?
Amnis Therapeutics is a biomedical engineering company that specializes in developing, manufacturing, and marketing lifesaving endovascular technologies for emergency situations.
What is the status of Amnis Therapeutics?
Amnis Therapeutics is currently inactive, having ceased operations in July 2021.
When was Amnis Therapeutics founded?
Amnis Therapeutics was founded in January 2007.
What is AneugraftDx?
AneugraftDx is a pericardium-covered coronary stent developed by Amnis Therapeutics for emergency vessel reconstruction in cases of acute rupture or dissection of a coronary artery, coronary aneurysm, or saphenous vein graft reperfusion.
What is AneugraftNx?
AneugraftNx is a neurovascular pericardium-covered stent from Amnis Therapeutics designed for intracranial indications such as aneurysms, ruptures, and cavernous carotid fistulas (CCFs).
What is the Golden Retriever product?
The Golden Retriever is a mechanical neurothrombectomy device developed by Amnis Therapeutics for the emergency treatment of acute ischemic stroke.
How much funding has Amnis Therapeutics raised in total?
Amnis Therapeutics has raised a total of $400,000.
Which investors participated in Amnis Therapeutics' funding rounds?
The Office of the Chief Scientist and MedTech Innovator participated in funding rounds for Amnis Therapeutics.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsLife Support
Technologies
Materials & Substances
Target customers
Healthcare & Life SciencesMedical Devices IndustryMedical EquipmentHealthcareProviders
Business model
B2B

Tags

medical-devicescardiologystentsurgerystrokecritical-carecardiovascularbiotechnologyneurology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)